Archive for the ‘diabetes’ Category
It would seem that resorting to legal means to avoid editorial notices doesn’t always work.
We’re coming to that conclusion after seeing yet another notice for Mario Saad, based at the University of Campinas in São Paulo, Brazil. In this case, it’s an expression of concern from the Journal of Endocrinology, on a 2005 paper that lists Saad as the second-to-last author. According to the notice, the journal is concerned the paper contains spliced and duplicated images; although the authors offered to repeat the experiments, the journal considered that potential delay “unacceptable.”
Despite Saad’s legal efforts, he is now up to 11 retractions, along with multiple expressions of concern.
Here’s the full text of the notice (which is paywalled, tsk tsk):
Researchers at Columbia University have retracted a 2013 paper in The Journal of Clinical Investigation, after uncovering abnormalities in the stem cell lines that undermined the conclusions in the paper.
Last year, corresponding author Dieter Egli discovered he could not reproduce key data in the 2013 paper because almost all the cell lines first author Haiqing Hua used contained abnormalities, casting doubt on the overall findings. When Egli reached out to Hua for answers, Hua could not explain the abnormalities. As a result, Hua and Egli agreed the paper should be retracted.
Since some of the details of how the paper ended up relying on abnormal cells remain unclear, the university confirmed to us that it is investigating the matter.
Here’s the retraction notice for “iPSC-derived β cells model diabetes due to glucokinase deficiency,” cited 42 times: Read the rest of this entry »
A department chair of a Swedish university asked to retract a 2010 study in Diabetes after none of the authors could explain image-related ambiguities.
The matter prompted particular attention because the paper’s first author, Pontus Almer Boström, had been found guilty of scientific misconduct by the University of Gothenburg in 2012, after Jan Borén noted some irregularities in data calculated by Boström. At that point, the research group combed the data to identify further issues arising from Boström’s work, and didn’t find any.
But last summer, when a user on PubPeer raised questions about some of the images in the 2010 paper, the matter was brought back into focus. According to Borén, they found “no evidence of scientific misconduct in this study.” But Boström had left the university in 2009 and could not be reached, the corresponding author had passed away, and the remaining co-authors hadn’t stayed in the field. So Borén decided it would be best to retract the study to avoid any “lingering questions.”
Here’s the retraction notice for “The SNARE Protein SNAP23 and the SNARE-Interacting Protein Munc18c in Human Skeletal Muscle Are Implicated in Insulin Resistance/Type 2 Diabetes,” in which Borén thanks “Peer 1″ on PubPeer for “detecting the ambiguities and bringing them to our attention:” Read the rest of this entry »
The notices keep coming for diabetes researcher Mario Saad.
Diabetes has just retracted two more of his papers, both of which had been flagged by expressions of concern, citing problems with duplications. What’s more, the journal added another expression of concern to a 2009 paper on which Saad — based at the University of Campinas in São Paulo, Brazil — is listed as last author, again over concerns of duplication.
This isn’t Saad’s first run-in with the journal: In 2015, the researcher sued the publisher, the American Diabetes Association, after it issued expressions of concern for four of his papers. Later that year, a judge dismissed Saad’s defamation suit. The journal eventually retracted the papers.
The latest articles flagged by Diabetes appear to be part of an intricate publishing web, as the journal suggests all papers have used features of previous papers, and also include elements that have been republished by subsequent articles.
The former president of the Joslin Diabetes Center has withdrawn a second article within a month of his first, and issued extensive corrections to another paper in the same journal, all due to figure errors.
In November, we reported that Carl Ronald Kahn — also affiliated with Harvard Medical School — had pulled a highly cited 2005 paper from The Journal of Clinical Investigation because of image duplication issues, which Kahn told us were introduced during figure assembly. This December, Kahn retracted a 2003 paper published in The Journal of Biological Chemistry (JBC)—again due to duplication issues that the authors believe “were inadvertently introduced during figure assembly.”
Here’s the retraction notice for “Bi-directional regulation of brown fat adipogenesis by the insulin receptor,” cited 46 times, according to Clarivate Analytics’ Web of Science, formerly part of Thomson Reuters:
2013 probably felt like it was going to be a great year for stem cell biologist Douglas Melton at Harvard. He had published a buzz-worthy paper in Cell about a new way to potentially boost insulin in diabetics, attracting significant media attention, and eventually gathering nearly 200 citations.
But 2016 is closing out on a less positive tone for Melton — today, he and his colleagues are retracting the paper, after multiple labs (including his own) couldn’t reproduce the findings.
Although the lab has itself already published two articles casting doubt on the original findings, Melton told Retraction Watch he chose to retract the paper to ensure there was no confusion about the original paper’s validity: Read the rest of this entry »
A researcher in Brazil is taking responsibility for accidentally mixing up images in three papers in the Journal of Biological Chemistry.
The corresponding author on the three papers told us the mistake happened because the studies were conducted simultaneously, and relied on one computer.
There’s a side note to these retractions: The co-author list on two papers includes names that should be fairly well-known to our readers — Mario Saad, the researcher who unsuccessfully sued the American Diabetes Association to stop retractions of his papers, and Rui Curi, a researcher whose legal threats assisted in the shutdown of Science-Fraud.org. This makes Saad’s ninth retraction.
According to the retraction notices, Lício Velloso — who, like his co-authors, is based at the University of Campinas in São Paulo, Brazil — assembled all the figures. He told Retraction Watch that the authors initially wanted to correct the papers, adding: Read the rest of this entry »
A researcher who received a lifetime funding ban for misconduct from a Canadian agency has logged her third retraction, after a re-analysis of her work unveiled “serious inconsistencies.”
In July, the Canadian Institutes of Health Research (CIHR) released a report about Sophie Jamal, following an investigation by her former employer, The Women’s College Hospital in Toronto, Canada. The probe concluded that Jamal had manipulated data, which resulted in her being banned from CIHR funding for life, and the retraction of a study in The Journal of the American Medical Association.
After that retraction, researchers that made up the the Canadian Multicentre Osteoporosis Study Group (CaMos) decided to take a second look at Jamal’s work. In August, we reported on a retraction that came out of that examination, in the American Journal of Kidney Diseases (AJKD). At the time, a senior researcher from the group told us the group had also requested another journal retract a CaMos paper.
The German Research Foundation (DFG) has announced today that it is withdrawing a professorship it awarded leading diabetes researcher Kathrin Maedler in 2014.
In recent years, Maedler — based at the University of Bremen in Germany — has faced questions about her work, including allegations of duplication and image manipulation. So far, she has issued one retraction, two expressions of concern, and multiple corrections. After an investigation, the University of Bremen concluded last month that Maedler’s work contained several duplications that were the result of negligence, noting there is not enough evidence to support charges of scientific misconduct.
But this hasn’t stopped the DFG from revoking the prestigious Heisenberg professorship it awarded Maedler in 2014. A Google-translated version of statement released by the DFG (in German) today concludes that Maedler did, in fact, commit misconduct, as she
Two papers evaluating glucose meters — used by diabetics to monitor blood sugar levels — suggested that a couple of the devices don’t work as well as they should. Perhaps unsurprisingly, the companies that sell those meters objected to how the studies were conducted. By all accounts, the companies appear to be justified in their complaints.
In both cases, researchers used blood drawn from veins to test the meters. But manufacturers of the WaveSense JAZZ and GlucoRx glucose meters said their devices are designed to work with fresh blood from a finger-prick. Both papers have now been retracted.
The retraction notice for “Technical and clinical accuracy of five blood glucose meters: clinical impact assessment using error grid analysis and insulin sliding scales,” published in 2015 in the Journal of Clinical Pathology, hints at the issue: